Review of Trends in Molecular Medicine by Zhou Rongbin/Huang Yi team: Inflammasome and HIV-1 infection and treatment

▲ Click the blue word above to follow CellPress Cell Science ▲ Life science Life science Human immunodeficiency virus type 1 (HIV-1) is the main cause of AIDS, which brings serious harm to people's life and health
.

Combination antiretroviral therapy (cART) refers to blocking viral replication by acting on different stages of the HIV-1 life cycle, and is currently one of the most effective treatments for HIV-1 infection
.

However, a small amount of HIV-1 provirus is latent in resting memory CD4+ T cells and cannot be completely eradicated, and some cART drugs can induce an inflammatory response with side effects
.

Therefore, exploring new strategies for the treatment of HIV-1 infection is a key scientific problem that needs to be solved urgently
.

Recent studies have found that HIV-1 infection is closely related to inflammasome activation, and a comprehensive understanding of the mechanisms of inflammasome activation and pyroptosis during HIV-1 infection will help develop treatments and interventions for HIV-1-related diseases
.

Recently, Professor Zhou Rongbin from the Department of Life Science and Medicine, University of Science and Technology of China and Professor Huang Yi from Jiangnan University School of Medicine published a paper entitled "Role of inflammasomes in HIV-1 infection and treatment" in the Cell Press journal Trends in Molecular Medicine.
Overview
.

This paper comprehensively and systematically summarizes the role and mechanism of the inflammasome and its mediated pyroptosis in HIV-1 infection and treatment, and discusses the possibility of the inflammasome as a therapeutic target for HIV-1-related diseases
.

▲